Business Wire

CBPE Acquires Majority Investment in CRO Simbec-Orion

Share

Simbec-Orion Group Limited (“Simbec-Orion”), a leading European full-service boutique clinical research organisation announced today that CBPE Capital LLP (“CBPE”) has acquired a majority stake in the company.

The investment, made through a management buy-out, will provide funding for further international growth and expansion by Simbec-Orion.

The investment made via the £459m CPBE Capital Fund IX, acquired the shareholding of the Wales Life Sciences Investment Fund LP (“WLSIF”) managed by Arix Capital Management Limited, a subsidiary of Arix Bioscience PLC. The financial details of the transaction have not been disclosed.

Simbec-Orion was formed by the merger of Simbec Research and Orion Clinical in June 2014, funded by WLSIF having acquired Simbec Research in May 2013.

Following several years of strong growth since 2014, Simbec-Orion has seen total revenue increase from £13.2m for the period to December 2014 to an expected outturn in excess of £30m for the year ended 31 December 2018.

Simbec-Orion provides a broad, full service CRO offering to its clients across all stages of development Phase I, II and III. Simbec-Orion designs, executes and delivers its clients’ clinical development needs across healthy volunteer and patient based clinical studies (including project management, clinical operations, data management, statistics, and regulatory affairs). In addition, Simbec-Orion offers a much broader range of services than its peers with the full range of additional clinical development services including central laboratory, IMP management and pharmacovigilance.

Simbec-Orion (www.SimbecOrion.com) focuses its breadth of resources on biotech companies and small-cap, specialty and mid-cap pharmaceutical companies. The Group concentrates on those in its areas of specialty particularly oncology, rare diseases and orphan indications, respiratory conditions and translational medicine (including FiH programmes).

CBPE’s investment will fund the continued growth of Simbec-Orion both organically and through acquisitions. CBPE has a history of backing experienced management teams with a track record in operational delivery and M&A.

CBPE (www.cbpecapital.com) has committed additional funds for future investment in operations, facilities and further expansion. The management team and CBPE intend to pursue further expansion of the Group geographically, particularly in the United States and Continental Europe, and across all its business units:

  • early stage healthy volunteer Phase I studies;
  • patient Phase I, II and III studies;
  • central laboratory; and
  • drug development consulting.

Professor Sir Christopher Evans, founder and Deputy Chairman of Arix Bioscience PLC, said, “We first backed Simbec Research in May 2013 through the Wales Life Sciences Investment Fund. Today, the Group is in strong financial health, the Welsh site employs more than 120 people and the Group approximately 300 people. The investment announcement today is excellent news for the company and for the Wales Life Sciences Investment Fund’s commitment”.

Ronald Openshaw, Chief Executive Simbec-Orion said, “The combination of Simbec Research and Orion Clinical provided the base to create a growing CRO in the mid-market. We created a strategy for a clearly defined and differentiated offering where our people can use their excellence, commitment and passion to improve patients lives. We are delighted to secure this return for the WLSIF and have clear plans with CBPE for the future growth of the Group”.

Anand Jain, Partner CBPE, said “We have been following Simbec-Orion’s growth since the merger in 2014 and are delighted to be supporting the business through the next phase of its development. We are excited about providing Simbec-Orion with the investment and support required to further develop their services and to expand geographically”.

Contact information

Simbec-Orion
Tel: +44-175-357-8080
Email: info@SimbecOrionCRO.com

Media House
Ramsay Smith
Tel: +44-207-710-0020
Email: ramsay@mediahouse.co.uk

CBPE Capital
Tel: +44-207-065-1100

Powerscourt:
Tel: +44-207-250-1446

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Announces Latest Data in Ongoing HIV Cure Research Program23.7.2019 20:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses

Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 15:30:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These

Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 15:00:00 CESTPress release

Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol

Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 14:12:00 CESTPress release

US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing

Andersen Global Expands into Ghana23.7.2019 13:30:00 CESTPress release

Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt